SAREPTA THERAPEUTICS, INC. Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer
SAREPTA THERAPEUTICS, INC. (SRPT) reported Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer of $72.56 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer · last filed 2026-08-05
- SAREPTA THERAPEUTICS, INC. revenue from collaborative arrangement, excluding revenue from contract with customer for the quarter ending 2026-06-30 was $72.56M, a 25.93% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. revenue from collaborative arrangement, excluding revenue from contract with customer for the quarter ending 2026-03-31 was $400.29M, a 200.22% increase year-over-year.
- SAREPTA THERAPEUTICS, INC. revenue from collaborative arrangement, excluding revenue from contract with customer for the quarter ending 2025-12-31 was $73.33M, a 262.02% increase year-over-year.
- SAREPTA THERAPEUTICS, INC. revenue from collaborative arrangement, excluding revenue from contract with customer for the quarter ending 2025-09-30 was $29.31M, a 21.63% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. revenue from collaborative arrangement, excluding revenue from contract with customer for fiscal 2025 was $333.94M, a 192.88% increase from fiscal 2024.
- SAREPTA THERAPEUTICS, INC. revenue from collaborative arrangement, excluding revenue from contract with customer for fiscal 2024 was $114.02M, a 15.80% increase from fiscal 2023.
- SAREPTA THERAPEUTICS, INC. revenue from collaborative arrangement, excluding revenue from contract with customer for fiscal 2023 was $98.46M, a 10.33% increase from fiscal 2022.
- SAREPTA THERAPEUTICS, INC. revenue from collaborative arrangement, excluding revenue from contract with customer for fiscal 2022 was $89.24M, a 0.27% decline from fiscal 2021.
| Period end | Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer 3 month | Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer 6 month | Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer 9 month | Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer 12 month |
|---|---|---|---|---|
| 2026-06-30 | $72.56M 10-Q · filed 2026-08-05 | $472.85M 10-Q · filed 2026-08-05 | $546.18M derived: sum of 3 quarters · filed 2026-08-05 | $575.49M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $400.29M 10-Q · filed 2026-05-06 | $473.62M derived: sum of 2 quarters · filed 2026-05-06 | $502.93M derived: sum of 3 quarters · filed 2026-05-06 | $600.90M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $73.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $102.64M derived: sum of 2 quarters · filed 2026-03-02 | $200.61M derived: sum of 3 quarters · filed 2026-08-05 | $333.94M 10-K · filed 2026-03-02 |
| 2025-09-30 | $29.31M 10-Q · filed 2025-11-06 | $127.28M derived: sum of 2 quarters · filed 2026-08-05 | $260.61M 10-Q · filed 2025-11-06 | $280.87M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $97.97M 10-Q · filed 2026-08-05 | $231.30M 10-Q · filed 2026-08-05 | $251.56M derived: sum of 3 quarters · filed 2026-08-05 | $288.96M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $133.33M 10-Q · filed 2026-05-06 | $153.59M derived: sum of 2 quarters · filed 2026-05-06 | $190.99M derived: sum of 3 quarters · filed 2026-05-06 | $193.37M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $20.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $57.66M derived: sum of 2 quarters · filed 2026-03-02 | $60.04M derived: sum of 3 quarters · filed 2026-03-02 | $114.02M 10-K · filed 2026-03-02 |
| 2024-09-30 | $37.40M 10-Q · filed 2025-11-06 | $39.78M derived: sum of 2 quarters · filed 2025-11-06 | $93.76M 10-Q · filed 2025-11-06 | $125.47M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $2.38M 10-Q · filed 2025-08-06 | $56.36M 10-Q · filed 2025-08-06 | $88.07M derived: sum of 3 quarters · filed 2026-03-02 | $110.57M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $53.98M 10-Q · filed 2025-05-06 | $85.69M derived: sum of 2 quarters · filed 2026-03-02 | $108.19M derived: sum of 3 quarters · filed 2026-03-02 | $130.44M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $31.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $54.20M derived: sum of 2 quarters · filed 2026-03-02 | $76.45M derived: sum of 3 quarters · filed 2026-03-02 | $98.46M 10-K · filed 2026-03-02 |
| 2023-09-30 | $22.50M 10-Q · filed 2024-11-06 | $44.74M derived: sum of 2 quarters · filed 2024-11-06 | $66.75M 10-Q · filed 2024-11-06 | $89.24M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $22.25M 10-Q · filed 2024-08-07 | $44.26M 10-Q · filed 2024-08-07 | $66.75M derived: sum of 3 quarters · filed 2025-02-28 | $89.24M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $22.00M 10-Q · filed 2024-05-01 | $44.50M derived: sum of 2 quarters · filed 2025-02-28 | $66.99M derived: sum of 3 quarters · filed 2025-02-28 | $89.24M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $22.49M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $44.99M derived: sum of 2 quarters · filed 2025-02-28 | $67.24M derived: sum of 3 quarters · filed 2025-02-28 | $89.24M 10-K · filed 2025-02-28 |
| 2022-09-30 | $22.50M 10-Q · filed 2023-11-01 | $44.74M derived: sum of 2 quarters · filed 2023-11-01 | $66.75M 10-Q · filed 2023-11-01 | $89.49M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $22.25M 10-Q · filed 2023-08-02 | $44.26M 10-Q · filed 2023-08-02 | $66.99M derived: sum of 3 quarters · filed 2024-02-28 | $89.49M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $22.00M 10-Q · filed 2023-05-02 | $44.74M derived: sum of 2 quarters · filed 2024-02-28 | $67.24M derived: sum of 3 quarters · filed 2024-02-28 | $89.49M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $22.74M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $45.23M derived: sum of 2 quarters · filed 2024-02-28 | $67.48M derived: sum of 3 quarters · filed 2024-02-28 | $89.49M 10-K · filed 2024-02-28 |
| 2021-09-30 | $22.50M 10-Q · filed 2022-11-02 | $44.74M derived: sum of 2 quarters · filed 2022-11-02 | $66.75M 10-Q · filed 2022-11-02 | $89.24M derived: sum of 4 quarters · filed 2022-11-02 |
| 2021-06-30 | $22.25M 10-Q · filed 2022-08-02 | $44.26M 10-Q · filed 2022-08-02 | $66.75M derived: sum of 3 quarters · filed 2022-08-02 | $89.24M derived: sum of 4 quarters · filed 2022-08-02 |
| 2021-03-31 | $22.00M 10-Q · filed 2022-05-04 | $44.50M derived: sum of 2 quarters · filed 2022-05-04 | $66.99M derived: sum of 3 quarters · filed 2022-05-04 | $93.01M derived: sum of 4 quarters · filed 2022-05-04 |
| 2020-12-31 | $22.49M 10-K · filed 2021-03-01 | $44.99M derived: sum of 2 quarters · filed 2021-11-03 | $71.01M derived: sum of 3 quarters · filed 2021-11-03 | $84.23M 10-K · filed 2023-02-28 |
| 2020-09-30 | $22.50M 10-Q · filed 2021-11-03 | $48.51M derived: sum of 2 quarters · filed 2021-11-03 | $61.74M 10-Q · filed 2021-11-03 | |
| 2020-06-30 | $26.02M 10-Q · filed 2021-08-04 | $39.24M 10-Q · filed 2021-08-04 | ||
| 2020-03-31 | $13.23M 10-Q · filed 2021-05-05 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |